Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
#Grippeviren ausbremsen! Medikamentös gegen#influenza! Atriva in diesem Artikel aus@DAZheute vorgestellt https://bit.ly/3bli1D1#flu#fightflu#Breakdown the#fluvirus! Medication against#influenza!pic.twitter.com/zZu6yxkQvV
-
Knowledge and science have no borders. Scientists and experts of all World are working together to find a solution to beat
#2019nCoV. German scientists are also contributing by working and sharing results.#UnityIsStrength#coronaviruspic.twitter.com/aaynqWz8gG
-
The world is under virus attack, but German scientists are already on the move.
@Tagesspiegel spoke with Prof. Dr. Ludwig, developer of@AtrivaTx’ host-targeting#antiviral candidate,#ATR002, about pandemic threats like#flu, SARS, MERS and#coronavirus. https://bit.ly/2O7CMrK pic.twitter.com/fT8OSsdVdv
-
The 3rd and last conference during the
@AtrivaTx’s San Francisco tour is the 15th Non-Dilutive Funding Summit@FreemindGrp. Meet our representatives to learn more about our potential in the development of host-targeting#antiviral therapies.#fightflu https://bit.ly/2QxOJs6 pic.twitter.com/tE26ECUJ8L
-
We look forward to telling you more about
#ATR002, our host-targeting approach to treat#flu, at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.@LSciNation https://bit.ly/2N0MUlh pic.twitter.com/is4vr7crmV
-
Learn more about
@AtrivaTx’s host-targeting therapy candidate#ATR002 against#flu, hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at#BiotechShowcase. Join us at 11:30, Franciscan D. https://bit.ly/39PxxWE pic.twitter.com/4C0P2MzBMb
-
@AtrivaTx kicks off the new year by travelling to#SanFrancisco to participate in three conferences. Dr. Lichtenberger, CEO, Dr. Wallasch, COO, and Dr. Björn Cochlovius, VP BD, will represent the Company and be available for networking and one-on-ones. https://bit.ly/36C8vbR pic.twitter.com/85h9KnIn4X
-
#Flu is always lurking, especially during the winter season, which impairs our immune system. At@AtrivaTx, we are developing a unique portfolio of broadly active and efficacious antiviral drugs. Stay warm and enjoy the#holidays.#MerryChristmas and#HappyNewYear from Atriva.pic.twitter.com/tX6m2UEZbv
-
#Congrats!@AtrivaTx’s co-founder and scientific advisor Prof. Ludwig, head of the Virology Institute at@WWU_Muenster is prominently featured in an interesting article on the#flu by@FAZ_NET: https://bit.ly/2sHonKS .#fightflu#innovation#ATR002#medicalneed@faznetpic.twitter.com/VGqIfflNW9
-
@rki_de reports the weekly status of Germany’s#flu incidence. As every year, the maximum is expected in February.@AtrivaTx’s is developing#ATR002 to reduce the occurrence of#flu and flu-like-illness by inhibiting the virus’ replication machinery independently of the strain.pic.twitter.com/4bdpkwZA7F
-
@AtrivaTx’s strategy and product candidate#ATR002 “may revolutionize treatment of#influenza and other severe respiratory viral infections” and be “a quantum leap in#antiviral respiratory therapies”. Learn more in the article by@bpdealmakers https://go.nature.com/2KDTqh0 pic.twitter.com/ATH2tiKcVY
-
Learn more about
#MEKinhibitors against#influenza and respiratory#viralinfections in the presentation of Dr. Rainer Lichtenberger, our CEO, today at 5.45 PM during the “Infectious Disease Company Presentations” section Level 1/Hall B1/Room 7#BIOEurope https://bit.ly/33TyLg4 pic.twitter.com/Q0I6A2NXoh
-
@AtrivaTx announces the successful conclusion of the Ph. I trial for#MEKinhibitor#ATR002 in#influenza. Dr. Lichtenberger, CEO: “An important milestone towards a novel flu drug against this public health danger and its threat of a new#pandemic” https://bit.ly/2CoVwgb pic.twitter.com/mPl6i4n9yw
-
On Nov 11
#BIOEurope, EU's largest life science partnering conference, starts in#Hamburg. Our CEO Dr. Lichtenberger is happy to discuss our lead product#ATR002 against#influenza,#hanta and other severe respiratory infections. Use#partneringONE@EBDgroup to set up a meeting!pic.twitter.com/lDsTrTORhb
-
Let’s go
#viral by spreading awareness - today is#WorldInfluenzaDay! Atriva commits to#fightflu with our first-in-class host-targeting MEK inhibitor#ATR002. We address the need for a novel, broadly active, resistance-avoiding therapy and for a prolonged treatment window.pic.twitter.com/DxGvbFPfNV
-
Atriva Theraputics is now also on Twitter! We can’t wait to tell you more about our lead product
#ATR002, a clinical- stage, first-in-class host-targeting agent that inhibits viral replication in#influenza and other respiratory infections. Stay tuned!pic.twitter.com/pNCZdmmkDn
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.